BDSX:NSD-Biodesix Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 1.32

Change

-0.13 (-8.97)%

Market Cap

USD 0.06B

Volume

0.11M

Avg Analyst Target

USD 10.00 (+657.58%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Biodesix Inc (BDSX) Stock Analysis:
Based on the Biodesix Inc stock forecasts from 3 analysts, the average analyst target price for Biodesix Inc is USD 10.00 over the next 12 months. Biodesix Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biodesix Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Biodesix Inc’s stock price was USD 1.32. Biodesix Inc’s stock price has changed by -22.35% over the past week, -19.02% over the past month and -90.61% over the last year.

About

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk o ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

-4.81 (-1.96%)

USD38.25B 53.46 32.96
IDXX IDEXX Laboratories Inc

-6.17 (-1.68%)

USD31.27B 43.70 29.92
ICLR ICON Public Limited Company

-1.31 (-0.60%)

USD17.57B 96.69 27.13
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
EXAS Exact Sciences Corporation

-4.11 (-7.90%)

USD9.35B N/A N/A
SYNH Syneos Health Inc

-0.91 (-1.27%)

USD7.27B 30.67 15.81
MEDP Medpace Holdings Inc

-0.40 (-0.30%)

USD4.50B 25.03 18.96
LNTH Lantheus Holdings Inc

-2.67 (-4.02%)

USD4.28B 2,335.00 206.62
NTRA Natera Inc

-1.71 (-4.38%)

USD3.85B N/A N/A
GH Guardant Health Inc

-0.71 (-1.87%)

USD3.75B N/A N/A

ETFs Containing BDSX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -75.05% 9% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.05% 9% F 6% F
Trailing 12 Months  
Capital Gain -91.13% 9% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.13% 9% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -28.10% 7% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.10% 7% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 38.58% 76% C 40% F
Risk Adjusted Return -72.82% 9% F 5% F
Market Capitalization 0.06B 29% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.57 11% F 11% F
Price / Cash Flow Ratio -2.09 53% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -234.25% 4% F 5% F
Return on Invested Capital -82.98% 16% F 13% F
Return on Assets -34.65% 17% F 10% F
Debt to Equity Ratio 50.66% 40% F 38% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.99 91% A- 76% C
Short Percent 5.34% 42% F 32% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.